Johnson & Johnson’s smelly drug problem is rearing its ugly head, yet again. According to the Wall Street Journal, Johnson & Johnson’s McNeil Consumer Healthcare division is pulling about 60,912 bottles—one lot—of its musty smelling Extra-Strength Tylenol caplets in the United States. This, following what it says were “a small number of odor reports,†quoted […]
Johnson & Johnson’s smelly drug problem is rearing its ugly head, yet again. According to the Wall Street Journal, Johnson & Johnson’s McNeil Consumer Healthcare division is pulling about 60,912 bottles—one lot—of its musty smelling <"https://www.yourlawyer.com/topics/overview/Tylenol-Liver-Damage-Injury-Lawsuit-Lawyer">Extra-Strength Tylenol caplets in the United States. This, following what it says were “a small number of odor reports,†quoted the Journal.
The stench appears to come from a chemical preservative—TBA—used in wood shipping pallets. 2,4,6 tribromoanisole (TBA) is a byproduct of a chemical preservative used on wood pallets on which products are transported and stored. TBA has been behind a number of musty smelling Johnson & Johnson drug recalls in recent months. Previously, Johnson & Johnson said it had taken steps to minimize TBA contamination that involved mandating its suppliers confirm that TBA pallets are not used. Still, the stinky recalls continue.
The Journal has been keeping track of the seemingly never-ending Johnson & Johnson recalls, noting that—to date—the recalls have cost the drug giant some $900 million dollars, just in sales and just in 2010. Many of the recalls involved the same odor problems that resulted in today’s action. Those include
• 16,000 bottles of Risperdal
• About 2,000 bottles of Prezista in four European countries
• About 57,000 bottles of Topamax.
• 34,000 bottles of Tylenol 8-Hour Extended Release Caplets (issued by J&J’s McNeil Consumer Healthcare unit)
• 127,000 bottles of Tylenol 8-Hour caplets: Musty odor.
• Tylenol Arthritis Pain Caplets
Johnson & Johnson recalls for musty odors and other problems have involved 200 million bottles of medications. Earlier this year, the company’s Ortho-McNeil-Janssen Pharmaceuticals division recalled prefilled Invega Sustenna syringe, while its Ethicon unit recalled a number of surgical drainage products because of sterility issues. Other Johnson & Johnson recalls have involved two DePuy hip replacement implants sold by its DePuy Orthopaedics unit, insulin pump cartidges made by its Animas unit, 1-Day Acuvue TruEye contact lenses, and Simponi injection pens.